{{AfC submission|t||ts=20250206180102|u=30Four|ns=118|demo=}}
{{AfC submission|t||ts=20250206180102|u=30Four|ns=118|demo=}}
{{Infobox company
| name =
| logo =
| logo_class =
| logo_size =
| logo_upright =
| logo_alt =
| logo_caption =
| image =
| image_size =
| image_upright =
| image_alt =
| image_caption =
| trade_name =
| native_name =
| native_name_lang =
| romanized_name =
| former_name =
| type =
| traded_as = {{NASDAQ|FTRP}}
| ISIN =
| industry = [[Psychotherapy]]
| genre =
| predecessor =
| founded = {{Start date and age|2019|04}}
| founders = {{Plainlist|
* Ronan Levy
* Joseph del Moral
* Hanna’s Fleima
* Ryan Yermus
* Mujeb jaferi}}
| defunct = {{End date|2022|05}}
| fate =
| successors = Field Trip H&W, Reunion Neuroscience
| hq_location =
| hq_location_city = [[Toronto]]
| hq_location_country = [[Canada]]
| num_locations =
| num_locations_year =
| area_served =
| key_people =
| products =
| production =
| production_year =
| brands =
| services = [[Ketamine-assisted psychotherapy]]
| revenue =
| revenue_year =
| operating_income =
| income_year =
| net_income =
| net_income_year =
| aum =
| assets =
| assets_year =
| equity =
| equity_year =
| owner =
| members =
| members_year =
| num_employees =
| num_employees_year =
| parent =
| divisions =
| SUBSID =
| module =
| ratio =
| rating =
| website =
| footnotes =
| embed =
}}
”’ Field Trip Health ”’ was a Canadian [[Ketamine-assisted psychotherapy|ketamine-assisted therapy]]company.{{cite news |last=Gunter |first=Marc |title=The Collapse of Field Trip Health |url=https://www.lucid.news/the-collapse-of-field-trip-health/ |work=Lucid News |date=1 June 2023}} It was founded in April 2019 by Ronan Levy, Joseph del Moral, Hannan Fleiman, Ryan Yermus and Mujeeb Jafferi.{{cite news |last=Yakowicz |first=Will |title=Ketamine Clinic Company Field Trip Health Debuts On Nasdaq |url=https://www.forbes.com/sites/willyakowicz/2021/07/29/ketamine-clinic-company-field-trip-health-debuts-on-nasdaq/ |work=Forbes |date=29 July 2021}}
”’ Field Trip Health ”’ was a Canadian [[Ketamine-assisted psychotherapy|ketamine-assisted therapy]]company.{{cite news |last=Gunter |first=Marc |title=The Collapse of Field Trip Health |url=https://www.lucid.news/the-collapse-of-field-trip-health/ |work=Lucid News |date=1 June 2023}} It was founded in April 2019 by Ronan Levy, Joseph del Moral, Hannan Fleiman, Ryan Yermus and Mujeeb Jafferi.{{cite news |last=Yakowicz |first=Will |title=Ketamine Clinic Company Field Trip Health Debuts On Nasdaq |url=https://www.forbes.com/sites/willyakowicz/2021/07/29/ketamine-clinic-company-field-trip-health-debuts-on-nasdaq/ |work=Forbes |date=29 July 2021}}
===Reunion Neuroscience===
===Reunion Neuroscience===
In June 2023, MPM Bioimpact acquired Reunion Neurosciences for $13.1 million, transitioning it into a private company.{{cite news |last=Patchen |first=Tyler |title=Novo-Backed Reunion Raises $103M Series A Financing for Psychedelic Trial |url=https://www.biospace.com/novo-holdings-backed-reunion-neuroscience-raises-103m-series-a-financing-for-psychedelic-trial |work=BioSpace |date=3 May 2024}}
In June 2023, MPM Bioimpact acquired Reunion for $13.1 million, transitioning it into a private company.{{cite news |last=Patchen |first=Tyler |title=Novo-Backed Reunion Raises $103M Series A Financing for Psychedelic Trial |url=https://www.biospace.com/novo-holdings-backed-reunion-neuroscience-raises-103m-series-a-financing-for-psychedelic-trial |work=BioSpace |date=3 May 2024}}
In May 2024, Reunion Neuroscience raised $103 million in Series A funding. The company was reported as “developing serotonergic psilocybin-like compounds initially for treating postnatal depression”, referring to [[RE-104]].{{cite news |last=Dorey |first=Emma |title=Biopharma deals highlight innovative approaches to treating neurological diseases |url=https://www.nature.com/articles/d43747-024-00091-x |work=Nature |date=2 September 2024}} The funds are planned to be used in support of a Phase II trial of the compound.
In May 2024, Reunion Neuroscience raised $103 million in Series A funding. The company was reported as “developing serotonergic psilocybin-like compounds initially for treating postnatal depression”, referring to [[RE-104]].{{cite news |last=Dorey |first=Emma |title=Biopharma deals highlight innovative approaches to treating neurological diseases |url=https://www.nature.com/articles/d43747-024-00091-x |work=Nature |date=2 September 2024}} The funds are planned to be used in support of a Phase II trial of the compound.
 |
This is a draft Articles for creation (AfC) submission. It is not currently pending review. While there are no deadlines, abandoned drafts may be deleted after six months. To edit the draft click on the “Edit” tab at the top of the window. To be accepted, a draft should: It is strongly discouraged to write about yourself, your business or employer. If you do so, you must declare it. Where to get help
Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomyand Women scientists tags. |
Field Trip Health was a Canadian ketamine-assisted therapy company.[1] It was founded in April 2019 by Ronan Levy, Joseph del Moral, Hannan Fleiman, Ryan Yermus and Mujeeb Jafferi.[2]
In May 2022, the company split into two separate, independent entities: Field Trip Health and Wellness and Reunion Neuroscience.[3] Field Trip Health and Wellness is now defunct with its assets acquired by two different companies,[1] while Reunion Neuroscience is still active as of 2024.[4]
Field Trip Health was founded in April 2019 by Ronan Levy, Joseph del Moral, Hannan Fleiman, Ryan Yermus and Mujeeb Jafferi.[2] All of the cofounders, except for Jafferi, previously worked together in the Canadian cannabis industry.[5]
The company was developing the psychedelic molecule, FT-104. The compound targeted the 5-HT2A receptor in the brain, the same receptor that psilocybin targets, and intended to produce a hallucinogenic effect that lasted roughly two hours, or approximately half the time a psychedelic experience with magic mushrooms lasts.[6]
The company went public on the Canadian Securities Exchange in October 2020, completing a reverse takeover of the Newton Energy Corporation, an oil and gas company.[5] It would later be listed on the Nasdaq in July 2021.[2]
In May 2022, Field Trip Health’s board voted to split the company into two independent entities. The company would split into “Field Trip Discovery”, focusing on the research and development of psychedelic therapies, and “Field Trip Health and Wellness”, focusing on its medical care offerings. Field Trip Discovery would also rebrand to Reunion Neuroscience.[3]
Field Trip Health and Wellness
[edit]
In January 2023, Field Trip Health and Wellness faced both “claims or potential claims” of over $59 million. Two months later, the company laid off a majority of its staff, closed clinics, and sought protection from creditors under the Canadian Companies’ Creditors Arrangement Act. Throughout the entirety of the company’s existence, close to CA$100 million of investor’s money was spent in an attempt to make Field Trip a successful company. The company’s three American clinics (New York, Washington, D.C., and California) were acquired by Stella, a healthcare company, for $751,770, and its Canadian clinics (Toronto and Vancouver) were acquired by the Canadian Centre for Psychedelic Healing for $627,900. Each buyer actively offers ketamine treatments.[1] In May 2023, the company sold its Jamaican research and cultivation laboratory where it grew psilocybin mushrooms for $350,000 to Jamaican businessman William Mahfood.[1] All proceeds from these sales were distributed to creditors.[1]
Ultimately, the American assets and company name would be folded under the Stella brand. As part of the acquisition, co-founder Mujeeb Jafferi and chief technology officer Amardeep Manhas joined Stella, taking on the roles of president and clinics operation officer. Stella also received Field Trip’s advanced outcome data, research, and tech stack.[7]
Reunion Neuroscience
[edit]
In June 2023, MPM Bioimpact acquired Reunion Neuroscience for $13.1 million, transitioning it into a private company.[8]
In May 2024, Reunion Neuroscience raised $103 million in Series A funding. The company was reported as “developing serotonergic psilocybin-like compounds initially for treating postnatal depression”, referring to RE-104.[4] The funds are planned to be used in support of a Phase II trial of the compound.[8]
- ^ a b c d e Gunter, Marc (1 June 2023). “The Collapse of Field Trip Health”. Lucid News.
- ^ a b c Yakowicz, Will (29 July 2021). “Ketamine Clinic Company Field Trip Health Debuts On Nasdaq”. Forbes.
- ^ a b Calvillo, Natalia Buendia (May 322). “Field Trip to split into two independent companies”. Mugglehead Magazine.
- ^ a b Dorey, Emma (2 September 2024). “Biopharma deals highlight innovative approaches to treating neurological diseases”. Nature.
- ^ a b Yakowicz, Will (7 October 2020). “Field Trip Health, Another Psychedelic Therapy Company, Goes Public”. Forbes.
- ^ Yakowicz, Will (19 November 2021). “Inside The Race To Create A Two-Hour Psychedelic Therapy Experience”. Forbes.
- ^ Gliadkovskaya, Anastassia (28 June 2023). “PTSD treatment startup Stella acquires Field Trip’s US assets to scale, takes over clinic operations”. Fierce Healthcare.
- ^ a b Patch, Tyler (3 May 2024). “Novo-Backed Reunion Raises $103M Series A Financing for Psychedelic Trial”. BioSpace.
